Ketamine treatment for depression is not permanent. The antidepressant effects of a single infusion typically fade within one to two weeks, and even a full course of multiple infusions produces relief that lasts a median of about 18 days after the final session. Ketamine is best understood as a powerful but temporary tool that requires ongoing maintenance to sustain its benefits.
How Long a Single Infusion Lasts
A single ketamine infusion can produce noticeable mood improvement within hours, sometimes as fast as two hours after administration. But this rapid relief comes with an equally notable limitation: the benefits generally disappear within one week. In a randomized controlled trial published in the American Journal of Psychiatry, only 27% of participants met the threshold for antidepressant response 24 hours after a single infusion, and just 5% reached full remission.
This is why clinics rarely offer just one session. A standard induction course involves six infusions over two to three weeks, designed to build on each session’s effects. After that full series, response rates climb significantly, reaching roughly 59% to 71% depending on the study. About 23% of patients achieve full remission, meaning their depression scores drop to near-normal levels.
What Happens After a Full Course
Even after completing a full induction series, relapse is the norm once infusions stop. Among patients who responded well to a course of six infusions, the median time to relapse was 18 days after the last session. Some people hold their gains longer, others less, but the pattern is consistent across studies: symptoms return after treatment ends.
A separate trial comparing single versus repeated ketamine sessions found that multiple doses extended the median time before relapse from about 2 weeks to 6 weeks, a meaningful improvement but far from permanent. The American Journal of Psychiatry has noted directly that “an effective strategy to maintain antidepressant response in patients after cessation of infusions remains elusive.”
Why the Effects Are Temporary
Ketamine works partly by triggering a burst of new connections between brain cells, particularly in the prefrontal cortex, the region involved in mood regulation and decision-making. Within two hours of a dose, the brain’s potential for growing new dendritic spines (the tiny projections that allow neurons to communicate) jumps to about 50%. New spine growth becomes visible within 12 to 24 hours.
But this window of heightened brain plasticity is brief. The elevated potential for new connections dissipates by about 12 hours after the dose. The spines that do form can persist longer, and researchers believe they contribute to the days or weeks of mood improvement that follow. Over time, though, without additional stimulation, these gains erode. The brain doesn’t permanently rewire itself from a short course of treatment, especially when the underlying conditions that contributed to depression, such as chronic stress or neurochemical imbalances, remain in play.
Maintenance Sessions and Long-Term Management
Because relapse is expected, most treatment protocols include ongoing “booster” sessions after the initial induction phase. The frequency varies from person to person, typically ranging from every 4 weeks to every 3 months. Your provider adjusts the schedule based on how long your symptom relief lasts between sessions.
The FDA-approved nasal spray form of ketamine (esketamine, sold as Spravato) follows a structured maintenance schedule. After twice-weekly sessions during a 4-week induction phase, patients move to individualized dosing of once weekly, every other week, or once monthly. In long-term data from the SUSTAIN-3 trial, the majority of patients needed either weekly or every-other-week sessions to maintain clinical stability. This is an ongoing commitment, not a one-time fix.
Combining Ketamine With Therapy
One of the more promising approaches for extending ketamine’s benefits involves pairing it with psychotherapy. A large retrospective study of ketamine-assisted psychotherapy found that 50% to 75% of patients experienced clinically meaningful improvement at 3 months, with 48% to 70% still reporting meaningful gains at 6 months. These effects persisted up to 5 months after the last dosing session, notably longer than ketamine alone typically provides.
The rationale makes biological sense. If ketamine opens a temporary window of brain plasticity, therapy during that window may help solidify new thought patterns and coping strategies into the brain’s refreshed circuitry. This combination doesn’t make treatment permanent either, but it appears to stretch the duration of benefit and may reduce how frequently booster sessions are needed.
Remission vs. Cure
Medical literature on ketamine consistently uses the word “remission” rather than “cure.” Remission means your symptoms have dropped below a clinical threshold, not that the underlying vulnerability to depression has been eliminated. This distinction matters for setting realistic expectations. Some patients do achieve sustained remission for months or longer with maintenance treatment, but they remain on a treatment plan rather than being declared cured.
The antidepressant effects of ketamine are also described in research as “transient” by default. Repeated dosing can prolong them, and combining ketamine with therapy or other antidepressants may extend them further, but no current evidence supports the idea that any number of ketamine sessions produces a permanent resolution of depression.
Safety of Long-Term Use
Because ketamine requires ongoing sessions, the safety of prolonged use matters. At therapeutic doses administered in a clinical setting, short-term side effects are well-documented and generally manageable: dissociation, sedation, dizziness, and temporary increases in blood pressure. These resolve within hours of each session.
Long-term safety data from supervised medical use is still limited. What does exist comes largely from studies of chronic recreational users consuming far higher doses (averaging 2.4 grams per day for 2 to nearly 10 years). In those populations, researchers observed reduced gray matter volume, impaired white matter integrity, and cognitive problems including memory loss. These structural brain changes were most pronounced after more than 3 years of heavy use. Clinical doses are a fraction of recreational doses, but the findings underscore why ongoing medical supervision and the lowest effective frequency matter for anyone on a long-term maintenance plan.